Entero Healthcare Solutions Limited has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26 to the Bombay Stock Exchange and National Stock Exchange of India. The filing, dated July 27, 2026, discloses a consolidated turnover of ₹65,91,21,21,789.48 and a net worth of ₹16,88,61,04,602.23 as of March 31, 2026. The report provides a comprehensive overview of the company’s operational footprint, which includes 48 subsidiaries and 137 offices nationwide, while detailing its adherence to regulatory standards under Regulation 34(2)(f) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The company operates exclusively within India, serving 21 states and union territories through a business-to-business model that caters to retail pharmacies, hospitals, nursing homes, and clinics. Entero Healthcare does not engage in export activities, meaning its entire turnover is derived from domestic distribution and marketing of pharmaceuticals, surgical items, and allied healthcare products. The reporting boundary encompasses the consolidated financial statements of the listed entity and all its subsidiaries.

Organizational Structure and Subsidiaries

As of the end of FY26, Entero Healthcare manages a network of 48 subsidiaries. During the reporting period, the company underwent several structural changes. Chethana Pharma Distributors Private Limited and CPD Pharma Private Limited, wholly-owned subsidiaries of Rada Medisolutions Private Limited, were merged via the fast-track route effective April 15, 2025. Conversely, three non-operational entities—Zennx Software Private Limited, Quomed Lifesciences Private Limited, and Rimedio Pharma Private Limited—were struck off on May 01, 2025, June 02, 2025, and June 05, 2025, respectively. Additionally, the company divested its 100% equity stake in Suprabhat Pharmaceuticals Private Limited by selling it back to its erstwhile promoters, removing it from the subsidiary list.

Employee Demographics and Welfare

The workforce comprises 4,943 employees and 27 workers. Among employees, 4,671 are permanent, with males constituting 73.71% and females 26.29% of this segment. The remaining 272 employees are non-permanent. Worker demographics show 27 permanent workers, with females representing 62.96% of this small cohort. The company reported no differently abled employees or workers during the period.

Turnover rates for permanent employees stood at 35.94% in FY26, a slight decrease from 38.27% in FY25. For permanent workers, the turnover rate was 20.00%, compared to 0.00% in the previous year. Women representation remains significant at the leadership level, with two women on the eight-member Board of Directors (25.00%) and one woman among the two Key Managerial Personnel (50.00%).

Environmental Impact and Resource Usage

Entero Healthcare disclosed total energy consumption from non-renewable sources at 2,25,67,219.85 Megajoules in FY26, up from 1,90,83,596.95 Megajoules in FY25. This increase is reflected in the energy intensity per rupee of turnover, which adjusted for Purchasing Power Parity (PPP), rose from 0.0077 to 0.0069 Megajoules/Rs. The company consumed 11,160 kilolitres of water, sourced entirely from third parties, with an intensity of 0.0000034 kilolitres/Rs. adjusted for PPP.

Greenhouse gas emissions saw a mixed trend. Scope 1 emissions decreased significantly to 744.18 metric tonnes of CO2 equivalent from 1,270.56 in FY25. However, Scope 2 emissions increased to 4,282.00 metric tonnes from 4,113.21. Total waste generated rose to 870.00 metric tonnes, primarily consisting of cartons and food waste, with no recycling or recovery operations reported. All waste was disposed of via landfilling.

Governance and Compliance

The company reported no fines, penalties, or legal actions related to bribery, corruption, or conflict of interest during FY26. One employee-related complaint was received via the SCORES portal but was resolved internally and closed. The Board of Directors oversees the implementation of business responsibility policies, with Managing Director Prabhat Agrawal identified as the highest authority responsible. The company maintains policies on attendance, medical claims, travel, conflict of interest, and grievance redressal, though these do not currently extend to value chain partners.

Entero Healthcare Solutions Limited has released its Annual Report for the financial year 2025-26, alongside the Notice convening its 8th Annual General Meeting (AGM) scheduled for Wednesday, August 19, 2026, at 12:30 p.m. (IST), to be held through Video Conferencing (VC)/Other Audio Visual Means (OAVM). The filing was made with BSE Limited and National Stock Exchange of India Limited on July 27, 2026.

Key AGM Details

The following table summarises the schedule for the 8th AGM:

FY26 Financial Performance

FY26 marked a significant milestone in the company's evolution as an integrated healthcare supply chain platform. Consolidated revenue from operations grew 29.35% year-on-year to INR 65,912.12 million (FY25: INR 50,957.80 million), driven by 13.4% organic growth and 16% inorganic contribution. During the same period, the Indian Pharmaceutical Market grew by approximately 10%, reflecting continued market share gains by the company.

The following table presents the consolidated and standalone financial highlights for FY 2025-26:

Gross profit rose 39.91% year-on-year to INR 680.38 crore, with gross margins improving 78 basis points to 10.32%. EBITDA for the year stood at INR 265.96 crore, growing 55.03% year-on-year, with EBITDA margins improving 67 basis points to 4.03%. Profit After Tax (PAT) grew 35.75% to INR 145.84 crore (PAT margin: 2.21%), notwithstanding a one-time exceptional charge of INR 6.1 crore (net of tax) arising from the implementation of the new Labour Code.

Operating Cash Flow and Return Metrics

A notable highlight of FY26 was a meaningful improvement in operating cash flow, with OCF improving significantly from an outflow of INR 76.90 crore in FY25 to a net cash inflow from operations of approximately INR 96.20 crore in FY26, driven by better inventory management, tighter receivables control, and improved EBITDA margins.

Return metrics also strengthened considerably during the year:

Key Financial Ratios (Consolidated Basis)

The following table presents key financial ratios as disclosed in the Annual Report:

Operational Scale and Network

The company's platform as at FY26 serves over 105,300 retail pharmacy customers, 3,600+ hospital customers, and operates across 523 districts, supported by 136 warehouses and relationships with 3,300+ manufacturers. The portfolio spans 97,500+ SKUs handled. The company operates across 21 States & UTs with 6.29 lakh+ sq. ft. of warehousing space across 50 cities.

Strategic Acquisitions and MedTech Expansion

During FY26, the company completed seven strategic acquisitions across pharmaceutical distribution and the MedTech segment, contributing aggregate annualised revenue of over ₹1,000 crore. Three of these acquisitions were in the MedTech segment:

• Anand Chemiceutics Private Limited (51.51% stake) — leading IVD and MedTech distributor
• Ace Cardiopathy Solutions Private Limited (60% stake) — cardiovascular care MedTech distributor
• Bioaide Technologies Private Limited (80% stake) — focused on interventional cardiology, ENT, wound management, and neuropsychiatry

Additional acquisitions in pharmaceutical distribution included Ramson Medical Distributors Private Limited (70%), Sai RK Pharma Private Limited (70%), Well Wisher Pharma Private Limited (70%), and Anand Medilink Private Limited (80%). The MedTech vertical is expected to cross ₹1,000 crore in annualised revenue in FY27.

Dividend and Share Capital

The Board has not recommended any dividend for FY 2025-26 in order to conserve resources. During FY 2025-26, the paid-up equity share capital increased from Rs. 43,50,77,070/- to Rs. 43,51,09,370/-, pursuant to the allotment of 3,230 equity shares under the Entero Employees Stock Option Plan, 2023 (ESOP 2023). As on March 31, 2026, the company had 48 subsidiaries. India Ratings and Research affirmed the company's credit rating at 'IND A-' with a stable outlook during the year.

AGM Business and Director Appointments

The 8th AGM will consider ordinary business including adoption of audited financial statements for FY 2025-26 and re-appointment of Mr. Arun Sadhanandham (DIN: 08445197) as a Non-Executive Non-Independent Director, who retires by rotation. Special business includes approval of remuneration for Managing Director & CEO Mr. Prabhat Agrawal and Whole-time Director & COO Mr. Prem Sethi for their remaining tenures up to August 25, 2028, as well as re-appointment of Mr. Sujesh Vasudevan (DIN: 08240092) as Non-Executive Independent Director for a second term of 5 years (August 25, 2026 to August 24, 2031) and re-appointment of Ms. Sandhya Gadkari Sharma (DIN: 02005378) as Non-Executive Independent Director for a second term of 4 years (August 25, 2026 to August 24, 2030).